Incyte Near $2 Billion Deal for Star Therapeutics
Incyte Corp (INCY) is reportedly close to acquiring privately held Star Therapeutics in a deal valued at up to $2 billion, according to the Financial Times. The acquisition aligns with mid-sized drugmakers' strategy of pursuing mergers and acquisitions to strengthen their product pipelines.
Tickers: $INCY
Topics: biotech M&A pharmaceuticals